BioSpace News Archive

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of its upsized initial public offering of 60,000,000 shares of Class A common stock at a public offering price of $27.00 per share, before underwriting discounts and commissions, for gross proceeds of $1,620,000,000.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has approved XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with multiple myeloma (MM)

Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society for Medical Oncology (ESMO) Asia Virtual Congress 2020 from November 20-22, 2020.

AVROBIO, Inc., a leading clinical-stage gene therapy company, announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.

William H. Peranteau, MD, fetal surgeon and researcher, will be inaugural chair holder

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today confirmed it will host a virtual Investor Day on December 14, 2020 from 1 pm to 3:30 pm Eastern Time

Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA’s industry-leading DCT practice

Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics, today reported third quarter 2020 financial results and operational progress.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020.

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020, at 8:00 a.m. ET.